• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

骨髓增殖性肿瘤和骨髓增生异常/骨髓增殖性肿瘤中的基因改变——WHO-HAEM5实用指南

Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms - a practical guide to WHO-HAEM5.

作者信息

Kühn Constanze, Hörst Katharina, Kvasnicka Hans M, Hochhaus Andreas, Reiter Andreas

机构信息

MLL - Munich Leukemia Laboratory Munich Germany.

University Hospital Institute for Pathology and Molecular Pathology Wuppertal Germany.

出版信息

Med Genet. 2024 Mar 6;36(1):31-38. doi: 10.1515/medgen-2024-2003. eCollection 2024 Apr.

DOI:10.1515/medgen-2024-2003
PMID:38835971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11006376/
Abstract

Within the World Health Organization (WHO) classification of haematopoietic neoplasms, particularly its fifth version from 2022 (WHO-HAEM5), myeloid neoplasms are not only grouped into myeloproliferative (MPN) and myelodysplastic neoplasms (MDS). There is also a group of haematological disorders that share features of both categories termed myelodysplastic /myeloproliferative neoplasms (MDS/MPN). In this article, we aim to provide a comprehensive and practical guide to WHO-HAEM5 highlighting the genetic alterations that underlie MPN and MDS/MPN. This guide provides an overview of the overlapping commonalities among these entities, as well as their unique characteristics.

摘要

在世界卫生组织（WHO）的造血系统肿瘤分类中，特别是其2022年的第五版（WHO-HAEM5），髓系肿瘤不仅被分为骨髓增殖性肿瘤（MPN）和骨髓增生异常肿瘤（MDS）。还有一组血液系统疾病兼具这两类疾病的特征，称为骨髓增生异常/骨髓增殖性肿瘤（MDS/MPN）。在本文中，我们旨在提供一份全面且实用的WHO-HAEM5指南，重点介绍MPN和MDS/MPN的潜在基因改变。本指南概述了这些实体之间的重叠共性及其独特特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/891af2257c57/j_medgen-2024-2003_cv_005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/80c3eb07d35a/j_medgen-2024-2003_fig_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/dd63fb14c452/j_medgen-2024-2003_fig_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/4e4a768d1e98/j_medgen-2024-2003_cv_003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/f3def1217303/j_medgen-2024-2003_cv_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/57b97cacec90/j_medgen-2024-2003_cv_004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/f6a2b39ac580/j_medgen-2024-2003_cv_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/891af2257c57/j_medgen-2024-2003_cv_005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/80c3eb07d35a/j_medgen-2024-2003_fig_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/dd63fb14c452/j_medgen-2024-2003_fig_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/4e4a768d1e98/j_medgen-2024-2003_cv_003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/f3def1217303/j_medgen-2024-2003_cv_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/57b97cacec90/j_medgen-2024-2003_cv_004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/f6a2b39ac580/j_medgen-2024-2003_cv_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae90/11006376/891af2257c57/j_medgen-2024-2003_cv_005.jpg

相似文献

1
Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms - a practical guide to WHO-HAEM5.骨髓增殖性肿瘤和骨髓增生异常/骨髓增殖性肿瘤中的基因改变——WHO-HAEM5实用指南
Med Genet. 2024 Mar 6;36(1):31-38. doi: 10.1515/medgen-2024-2003. eCollection 2024 Apr.
2
Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.混合性或重叠性骨髓增生异常/骨髓增殖性疾病——流行病学特征与概述
Front Oncol. 2021 Nov 16;11:778741. doi: 10.3389/fonc.2021.778741. eCollection 2021.
3
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.2022年世界卫生组织（WHO）和国际癌症研究机构（ICC）时代的骨髓增生异常综合征/骨髓增殖性重叠肿瘤及其鉴别诊断：重点综述
Cancers (Basel). 2023 Jun 13;15(12):3175. doi: 10.3390/cancers15123175.
4
Genetic studies in clonal haematopoiesis, myelodysplastic neoplasms and acute myeloid leukaemia - a practical guide to WHO-HAEM5.克隆性造血、骨髓增生异常肿瘤及急性髓系白血病的遗传学研究——WHO-HAEM5实用指南
Med Genet. 2024 Mar 6;36(1):21-29. doi: 10.1515/medgen-2024-2010. eCollection 2024 Apr.
5
Myelodysplastic/myeloproliferative neoplasms.骨髓增生异常/骨髓增殖性肿瘤。
Semin Diagn Pathol. 2011 Nov;28(4):283-97. doi: 10.1053/j.semdp.2011.07.002.
6
Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.骨髓增生异常综合征、骨髓增殖性肿瘤和骨髓增生异常/骨髓增殖性肿瘤突变谱的比较及意义：一项荟萃分析
Front Oncol. 2020 Oct 7;10:579221. doi: 10.3389/fonc.2020.579221. eCollection 2020.
7
Advances in myelodysplastic/myeloproliferative neoplasms.骨髓增生异常/骨髓增殖性肿瘤的进展
Virchows Arch. 2023 Jan;482(1):69-83. doi: 10.1007/s00428-022-03465-7. Epub 2022 Dec 5.
8
Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).骨髓增生异常/骨髓增殖性肿瘤（MDS/MPN）面临的挑战。
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):1-8. doi: 10.1016/j.clml.2018.11.019. Epub 2018 Nov 23.
9
The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.治疗骨髓增生异常综合征/骨髓增殖性肿瘤的挑战
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S37-S42. doi: 10.1016/j.clml.2017.02.012.
10
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.骨髓增生异常/骨髓增殖性肿瘤：具有发育异常特征的骨髓增殖性疾病。
Leukemia. 2008 Jul;22(7):1308-19. doi: 10.1038/leu.2008.119. Epub 2008 May 15.

本文引用的文献

1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.原发性骨髓纤维化：2023年诊断、风险分层及管理的最新进展
Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6.
2
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.纤维化的持续指数化（CIF）：改善 MPN 患者的评估和分类。
Leukemia. 2023 Feb;37(2):348-358. doi: 10.1038/s41375-022-01773-0. Epub 2022 Dec 5.
3
Genetic basis and molecular profiling in myeloproliferative neoplasms.
骨髓增殖性肿瘤的遗传基础和分子谱分析。
Blood. 2023 Apr 20;141(16):1909-1921. doi: 10.1182/blood.2022017578.
4
Artificial intelligence in hematological diagnostics: Game changer or gadget?血液学诊断中的人工智能：变革者还是小玩意？
Blood Rev. 2023 Mar;58:101019. doi: 10.1016/j.blre.2022.101019. Epub 2022 Oct 7.
5
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.CML 分子监测的标准化：来自欧洲治疗和结果研究的结果和建议。
Leukemia. 2022 Jul;36(7):1834-1842. doi: 10.1038/s41375-022-01607-z. Epub 2022 May 25.
6
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.慢性髓单核细胞白血病：诊断、风险分层和治疗的 2022 年更新。
Am J Hematol. 2022 Mar 1;97(3):352-372. doi: 10.1002/ajh.26455. Epub 2022 Jan 27.
7
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
8
MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.MIPSS70+ 版本2.0：原发性骨髓纤维化的突变与核型增强国际预后评分系统
J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30.
9
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.GIPSS：原发性骨髓纤维化的基因启发预后评分系统。
Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.
10
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.原发性骨髓纤维化的修订细胞遗传学危险分层：基于 1002 例信息性患者的分析。
Leukemia. 2018 May;32(5):1189-1199. doi: 10.1038/s41375-018-0018-z. Epub 2018 Feb 2.